Equity Profile

ILMN

Illumina, Inc.

Health CareLife Sciences Tools & Services$28.8B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Illumina is managing costs and generating income.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market share and meet customer demand, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. They are known for their innovative technologies in genetic sequencing, which play a crucial role in advancing personalized medicine and genomic research.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In Q1-2026, Illumina reported an EPS of $1.15, surpassing estimates by 9.73%. The stock reacted positively, gaining 5.29% the following day.

Management Promises & Guidance

Continue to innovate in genetic sequencing technology.
Expand market presence in personalized medicine.
Focus on improving operational efficiency.

Expectations

Wall Street Expectations

Investors are generally optimistic about Illumina's upcoming earnings, given their strong track record of beating EPS estimates. However, the lack of revenue guidance may create uncertainty.

Bull Case

If Illumina continues its trend of beating EPS estimates, it could lead to significant stock price appreciation, especially if they provide positive commentary on future growth.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Illumina's history of beating EPS estimates, this number will be critical in determining market sentiment and stock movement post-earnings.

What is the outlook for revenue growth in the upcoming quarters?

Investors will closely monitor revenue growth to assess the company's ability to capitalize on market opportunities and sustain its competitive edge.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Illumina's ability to drive revenue growth through new product launches, which could significantly boost their EPS this quarter.

Supporting Evidence

Illumina has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting that traders expect a significant event.

Recent insider buying suggests confidence in the company's future performance.

Key Risk

If revenue growth comes in below expectations, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around Illumina's ability to maintain its growth trajectory amidst increasing competition and market challenges.

Bull Confirmed If

An EPS of $1.20 or higher would confirm the bull case and likely lead to a positive market reaction.

Bear Confirmed If

An EPS below $1.05 would confirm the bear case and could trigger a significant sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±19.18%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests the stock could rise by around 1.42% on the following day, reinforcing investor confidence.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance from management.

Miss

If Illumina misses EPS expectations, history suggests a potential decline of around 3.10%, which could raise concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive pressures in the genetic sequencing market.
3Insights into customer demand trends for Illumina's products.
4Any guidance on operational efficiencies and cost management strategies.
5Discussion on future growth opportunities in personalized medicine.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Illumina is managing costs and generating income.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market share and meet customer demand, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In Q1-2026, Illumina reported an EPS of $1.15, surpassing estimates by 9.73%. The stock reacted positively, gaining 5.29% the following day.

Management Promises & Guidance

Continue to innovate in genetic sequencing technology.
Expand market presence in personalized medicine.
Focus on improving operational efficiency.

Expectations

Wall Street Expectations

Investors are generally optimistic about Illumina's upcoming earnings, given their strong track record of beating EPS estimates. However, the lack of revenue guidance may create uncertainty.

Bull Case

If Illumina continues its trend of beating EPS estimates, it could lead to significant stock price appreciation, especially if they provide positive commentary on future growth.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Illumina's history of beating EPS estimates, this number will be critical in determining market sentiment and stock movement post-earnings.

What is the outlook for revenue growth in the upcoming quarters?

Investors will closely monitor revenue growth to assess the company's ability to capitalize on market opportunities and sustain its competitive edge.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Illumina's ability to drive revenue growth through new product launches, which could significantly boost their EPS this quarter.

Supporting Evidence

Illumina has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting that traders expect a significant event.

Recent insider buying suggests confidence in the company's future performance.

Key Risk

If revenue growth comes in below expectations, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around Illumina's ability to maintain its growth trajectory amidst increasing competition and market challenges.

Bull Confirmed If

An EPS of $1.20 or higher would confirm the bull case and likely lead to a positive market reaction.

Bear Confirmed If

An EPS below $1.05 would confirm the bear case and could trigger a significant sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±19.18%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests the stock could rise by around 1.42% on the following day, reinforcing investor confidence.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance from management.

Miss

If Illumina misses EPS expectations, history suggests a potential decline of around 3.10%, which could raise concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive pressures in the genetic sequencing market.
3Insights into customer demand trends for Illumina's products.
4Any guidance on operational efficiencies and cost management strategies.
5Discussion on future growth opportunities in personalized medicine.